vs
AST SpaceMobile, Inc.（ASTS）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是AST SpaceMobile, Inc.的1.2倍（$65.1M vs $54.3M），MESA LABORATORIES INC净利率更高（5.6% vs -136.2%，领先141.8%），AST SpaceMobile, Inc.同比增速更快（2758.2% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $-330.7M）
AST SpaceMobile是总部位于美国得克萨斯州米德兰的上市卫星设计与制造企业，目前正搭建SpaceMobile卫星星座，打造可直接对接未改装普通智能手机的天基蜂窝宽带网络，面向全球偏远及通信服务薄弱地区提供4G、5G宽带覆盖服务。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
ASTS vs MLAB — 直观对比
营收规模更大
MLAB
是对方的1.2倍
$54.3M
营收增速更快
ASTS
高出2754.5%
3.6%
净利率更高
MLAB
高出141.8%
-136.2%
自由现金流更多
MLAB
多$348.7M
$-330.7M
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $54.3M | $65.1M |
| 净利润 | $-74.0M | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | -175.0% | 12.2% |
| 净利率 | -136.2% | 5.6% |
| 营收同比 | 2758.2% | 3.6% |
| 净利润同比 | -106.3% | 316.6% |
| 每股收益（稀释后） | — | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTSMLAB
| Q4 25 | $54.3M | $65.1M | ||
| Q3 25 | $14.7M | $60.7M | ||
| Q2 25 | — | $59.5M | ||
| Q1 25 | — | $62.1M | ||
| Q4 24 | — | $62.8M | ||
| Q3 24 | — | $57.8M | ||
| Q2 24 | — | $58.2M | ||
| Q1 24 | — | $58.9M |
净利润ASTSMLAB
| Q4 25 | $-74.0M | $3.6M | ||
| Q3 25 | $-122.9M | $2.5M | ||
| Q2 25 | — | $4.7M | ||
| Q1 25 | — | $-7.1M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $3.4M | ||
| Q2 24 | — | $3.4M | ||
| Q1 24 | — | $-254.6M |
毛利率ASTSMLAB
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
营业利润率ASTSMLAB
| Q4 25 | -175.0% | 12.2% | ||
| Q3 25 | -1109.0% | 7.8% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 9.2% | ||
| Q3 24 | — | 6.1% | ||
| Q2 24 | — | 9.6% | ||
| Q1 24 | — | -460.6% |
净利率ASTSMLAB
| Q4 25 | -136.2% | 5.6% | ||
| Q3 25 | -833.7% | 4.1% | ||
| Q2 25 | — | 8.0% | ||
| Q1 25 | — | -11.4% | ||
| Q4 24 | — | -2.7% | ||
| Q3 24 | — | 5.9% | ||
| Q2 24 | — | 5.8% | ||
| Q1 24 | — | -432.2% |
每股收益（稀释后）ASTSMLAB
| Q4 25 | — | $0.65 | ||
| Q3 25 | — | $0.45 | ||
| Q2 25 | — | $0.85 | ||
| Q1 25 | — | $-1.30 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | — | $0.63 | ||
| Q2 24 | — | $0.62 | ||
| Q1 24 | — | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.3B | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $2.4B | $186.7M |
| 总资产 | $5.0B | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资ASTSMLAB
| Q4 25 | $4.3B | $29.0M | ||
| Q3 25 | $2.4B | $20.4M | ||
| Q2 25 | — | $21.3M | ||
| Q1 25 | — | $27.3M | ||
| Q4 24 | — | $27.3M | ||
| Q3 24 | — | $24.3M | ||
| Q2 24 | — | $28.5M | ||
| Q1 24 | — | $28.2M |
总债务ASTSMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益ASTSMLAB
| Q4 25 | $2.4B | $186.7M | ||
| Q3 25 | $1.6B | $178.5M | ||
| Q2 25 | — | $172.5M | ||
| Q1 25 | — | $159.8M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | — | $161.5M | ||
| Q2 24 | — | $150.7M | ||
| Q1 24 | — | $145.4M |
总资产ASTSMLAB
| Q4 25 | $5.0B | $434.8M | ||
| Q3 25 | $2.6B | $430.4M | ||
| Q2 25 | — | $435.7M | ||
| Q1 25 | — | $433.3M | ||
| Q4 24 | — | $433.3M | ||
| Q3 24 | — | $454.1M | ||
| Q2 24 | — | $440.4M | ||
| Q1 24 | — | $446.8M |
负债/权益比ASTSMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $65.0M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $-330.7M | $18.0M |
| 自由现金流率自由现金流/营收 | -609.0% | 27.7% |
| 资本支出强度资本支出/营收 | 728.7% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | $-790.4M | $37.9M |
8季度趋势，按日历期对齐
经营现金流ASTSMLAB
| Q4 25 | $65.0M | $18.8M | ||
| Q3 25 | $-64.5M | $8.2M | ||
| Q2 25 | — | $1.9M | ||
| Q1 25 | — | $12.7M | ||
| Q4 24 | — | $18.1M | ||
| Q3 24 | — | $5.3M | ||
| Q2 24 | — | $10.7M | ||
| Q1 24 | — | $12.9M |
自由现金流ASTSMLAB
| Q4 25 | $-330.7M | $18.0M | ||
| Q3 25 | $-302.9M | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | — | $17.3M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | — | $12.3M |
自由现金流率ASTSMLAB
| Q4 25 | -609.0% | 27.7% | ||
| Q3 25 | -2055.0% | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 19.2% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | 16.9% | ||
| Q1 24 | — | 21.0% |
资本支出强度ASTSMLAB
| Q4 25 | 728.7% | 1.1% | ||
| Q3 25 | 1617.6% | 1.8% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 0.9% |
现金转化率ASTSMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTS
| Products | $44.4M | 82% |
| Other | $7.8M | 14% |
| Sat Co | $2.1M | 4% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
